Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Anxiety-Related Coping Styles, Social Support, and Internet Use Disorder.

Jung S, Sindermann C, Li M, Wernicke J, Quan L, Ko HC, Montag C.

Front Psychiatry. 2019 Sep 24;10:640. doi: 10.3389/fpsyt.2019.00640. eCollection 2019.

2.

Depression Is Associated With the Absence of Sex Differences in the 2D:4D Ratio of the Right Hand.

Sanwald S, Widenhorn-Müller K, Wernicke J, Sindermann C, Kiefer M, Montag C.

Front Psychiatry. 2019 Jul 16;10:483. doi: 10.3389/fpsyt.2019.00483. eCollection 2019.

3.

Air moisture signals in a stable oxygen isotope chronology of dwarf shrubs from the central Tibetan Plateau.

Wernicke J, Stark G, Wang L, Grießinger J, Bräuning A.

Ann Bot. 2019 Aug 2;124(1):53-64. doi: 10.1093/aob/mcz030.

PMID:
31329817
4.

Foot massage evokes oxytocin release and activation of orbitofrontal cortex and superior temporal sulcus.

Li Q, Becker B, Wernicke J, Chen Y, Zhang Y, Li R, Le J, Kou J, Zhao W, Kendrick KM.

Psychoneuroendocrinology. 2019 Mar;101:193-203. doi: 10.1016/j.psyneuen.2018.11.016. Epub 2018 Nov 14.

PMID:
30469087
5.

Individual differences in tendencies to attention-deficit/hyperactivity disorder and emotionality: empirical evidence in young healthy adults from Germany and China.

Wernicke J, Li M, Sha P, Zhou M, Sindermann C, Becker B, Kendrick KM, Montag C.

Atten Defic Hyperact Disord. 2019 Jun;11(2):167-182. doi: 10.1007/s12402-018-0266-9. Epub 2018 Oct 10.

PMID:
30306405
6.

Pregnancy Outcome After First Trimester Use of Methyldopa: A Prospective Cohort Study.

Hoeltzenbein M, Beck E, Fietz AK, Wernicke J, Zinke S, Kayser A, Padberg S, Weber-Schoendorfer C, Meister R, Schaefer C.

Hypertension. 2017 Jul;70(1):201-208. doi: 10.1161/HYPERTENSIONAHA.117.09110. Epub 2017 May 22.

PMID:
28533329
7.

Air mass origin signals in δ 18O of tree-ring cellulose revealed by back-trajectory modeling at the monsoonal Tibetan plateau.

Wernicke J, Hochreuther P, Grießinger J, Zhu H, Wang L, Bräuning A.

Int J Biometeorol. 2017 Jun;61(6):1109-1124. doi: 10.1007/s00484-016-1292-y. Epub 2016 Dec 28.

PMID:
28032196
8.

Diagnoses of gastrointestinal cancers after gastrointestinal bleeding in patients receiving clopidogrel or warfarin.

Asiimwe A, Li JJ, Weerakkody G, Vangerow H, Delisle F, Benoit K, Heath L, Wernicke J, Motsko S.

Curr Drug Saf. 2013 Sep;8(4):261-9.

PMID:
24102361
9.

Efficacy of Duloxetine in Patients with Chronic Pain Conditions.

Skljarevski V, Zhang S, Iyengar S, D'Souza D, Alaka K, Chappell A, Wernicke J.

Curr Drug ther. 2011 Nov;6(4):296-303.

10.

Cumulative risk assessment of chemical exposures in urban environments.

Ragas AM, Oldenkamp R, Preeker NL, Wernicke J, Schlink U.

Environ Int. 2011 Jul;37(5):872-81. doi: 10.1016/j.envint.2011.02.015. Epub 2011 Mar 29.

PMID:
21450344
11.

Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysis.

Crucitti A, Zhang Q, Nilsson M, Brecht S, Yang CR, Wernicke J.

Curr Med Res Opin. 2010 Nov;26(11):2579-88. doi: 10.1185/03007991003769241. Epub 2010 Sep 27.

PMID:
20874076
12.

Evaluation of human mobility models, for exposure to air pollutants.

Schlink U, Strebel K, Loos M, Tuchscherer R, Richter M, Lange T, Wernicke J, Ragas A.

Sci Total Environ. 2010 Aug 15;408(18):3918-30. doi: 10.1016/j.scitotenv.2010.03.018. Epub 2010 Apr 24.

PMID:
20417545
13.

The placebo response in pain and depression: in search of a common pathway.

Wernicke JF, Ossanna MJ.

Front Biosci (Schol Ed). 2010 Jan 1;2:106-11. Review.

PMID:
20036932
14.

Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients.

Wasan AD, Ossanna MJ, Raskin J, Wernicke JF, Robinson MJ, Hall JA, Edwards SE, Lipsius S, Meyers AL, McCarberg BH.

Curr Drug Saf. 2009 Jan;4(1):22-9.

PMID:
19149522
15.

The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder.

Fishbain DA, Detke MJ, Wernicke J, Chappell AS, Kajdasz DK.

Curr Med Res Opin. 2008 Nov;24(11):3105-15. doi: 10.1185/03007990802429627 . Epub 2008 Oct 2.

PMID:
18828958
16.

Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions.

Wernicke JF, Prakash A, Kajdasz DK, Houston J.

J Diabetes Complications. 2009 Sep-Oct;23(5):349-59. doi: 10.1016/j.jdiacomp.2008.07.004. Epub 2008 Sep 2.

PMID:
18768332
17.

Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources.

Strombom I, Wernicke JF, Seeger J, D'Souza DN, Acharya N.

Curr Drug Saf. 2008 May;3(2):154-62.

PMID:
18690993
18.

Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events.

Wernicke J, Acharya N, Strombom I, Gahimer JL, D'Souza DN, DiPietro N, Uetrecht JP.

Curr Drug Saf. 2008 May;3(2):143-53. Review.

PMID:
18690992
19.

Hepatic effects of duloxetine-I: non-clinical and clinical trial data.

Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, D'Souza DN, Uetrecht JP.

Curr Drug Saf. 2008 May;3(2):132-42. Review. Erratum in: Curr Drug Saf. 2009 Jan;4(1):94.

PMID:
18690991
20.

Answers to the most common questions about the hepatic safety profile of duloxetine.

Wohlreich MM, Acharya N, Strombom I, Kuritzky L, Robinson M, Heinloth AN, Regev A, Wernicke JF.

Postgrad Med. 2008 Jul;120(2):111-8. doi: 10.3810/pgm.2008.07.1803. Review.

PMID:
18654076
21.

Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.

Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, Regev A, Wernicke JF.

Drug Saf. 2008;31(4):345-54.

PMID:
18366245
22.

Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials.

Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF.

J Womens Health (Larchmt). 2007 Oct;16(8):1145-56.

PMID:
17937567
23.

An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.

Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D'Souza DN, Iyengar S, Chappell AS.

Pain Med. 2007 Sep;8(6):503-13.

PMID:
17716324
24.

Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.

Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, Allen AJ, Ball S, Dunn D.

Dev Med Child Neurol. 2007 Jul;49(7):498-502.

25.

An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.

Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F.

Drug Saf. 2007;30(5):437-55.

PMID:
17472422
26.

A retrospective pooled analysis of duloxetine safety in 23,983 subjects.

Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L.

Curr Med Res Opin. 2007 Jan;23(1):175-84.

PMID:
17257478
27.

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations.

Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, Allen RR, Atkinson JH, Chandler J, Cleeland C, Cowan P, Dimitrova R, Dionne R, Farrar JT, Haythornthwaite JA, Hertz S, Jadad AR, Jensen MP, Kellstein D, Kerns RD, Manning DC, Martin S, Max MB, McDermott MP, McGrath P, Moulin DE, Nurmikko T, Quessy S, Raja S, Rappaport BA, Rauschkolb C, Robinson JP, Royal MA, Simon L, Stauffer JW, Stucki G, Tollett J, von Stein T, Wallace MS, Wernicke J, White RE, Williams AC, Witter J, Wyrwich KW; Initiative on Methods, Measurement and Pain Assessment in Clinical Trials.

Pain. 2006 Dec 5;125(3):208-15. Epub 2006 Oct 25. No abstract available.

PMID:
17069973
28.

A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J.

Neurology. 2006 Oct 24;67(8):1411-20.

PMID:
17060567
29.

Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial.

Wernicke JF, Raskin J, Rosen A, Pritchett YL, D'Souza DN, Iyengar S, Knopp K, Le TK.

Curr Ther Res Clin Exp. 2006 Sep;67(5):283-304. doi: 10.1016/j.curtheres.2006.10.001.

30.

Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain.

Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, Wernicke JF.

J Palliat Med. 2006 Feb;9(1):29-40.

PMID:
16430342
31.

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF.

Pain. 2005 Dec 15;119(1-3):5-15. Epub 2005 Nov 17.

PMID:
16298061
32.

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.

Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF.

Pain Med. 2005 Sep-Oct;6(5):346-56.

PMID:
16266355
33.

Fibromyalgia syndrome.

Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, Simon LS, Strand CV, Bramson C, Martin S, Wright TM, Littman B, Wernicke JF, Gendreau RM, Crofford LJ.

J Rheumatol. 2005 Nov;32(11):2270-7.

PMID:
16265715
34.

Safety and adverse event profile of duloxetine.

Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L.

Expert Opin Drug Saf. 2005 Nov;4(6):987-93. Review.

PMID:
16255658
35.
36.

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.

Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF.

J Atten Disord. 2004 Oct;8(2):45-52.

PMID:
15801334
37.

QT correction methods in children and adolescents.

Wernicke JF, Faries D, Breitung R, Girod D.

J Cardiovasc Electrophysiol. 2005 Jan;16(1):76-81.

PMID:
15673393
38.

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.

Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT.

Pain. 2005 Jan;113(1-2):9-19. Review. No abstract available.

PMID:
15621359
39.

Safety and side effect profile of fluoxetine.

Wernicke JF.

Expert Opin Drug Saf. 2004 Sep;3(5):495-504. Review.

PMID:
15335304
40.

Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.

Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D.

J Clin Psychopharmacol. 2004 Feb;24(1):30-5.

PMID:
14709944
41.

Effects of etherlipid analogs on cell membrane functions.

Berkovic D, Wernicke JH, Fleer EA.

J Exp Ther Oncol. 2003 Jul-Aug;3(4):185-93.

PMID:
14567289
42.

Cardiovascular effects of atomoxetine in children, adolescents, and adults.

Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J.

Drug Saf. 2003;26(10):729-40. Review.

PMID:
12862507
43.

Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.

Wernicke JF, Kratochvil CJ.

J Clin Psychiatry. 2002;63 Suppl 12:50-5. Review.

44.

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D.

Biol Psychiatry. 2003 Jan 15;53(2):112-20.

PMID:
12547466
45.

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D.

Am J Psychiatry. 2002 Nov;159(11):1896-901.

PMID:
12411225
46.

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D.

J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84.

PMID:
12108801
47.

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group.

Pediatrics. 2001 Nov;108(5):E83.

PMID:
11694667
48.

A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders.

Jobe PC, Dailey JW, Wernicke JF.

Crit Rev Neurobiol. 1999;13(4):317-56. Review.

PMID:
11028680
49.
50.

Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group.

Salinsky MC, Uthman BM, Ristanovic RK, Wernicke JF, Tarver WB.

Arch Neurol. 1996 Nov;53(11):1176-80.

PMID:
8912492

Supplemental Content

Loading ...
Support Center